The Epidermal Growth Factor Receptor (EGFR; ErbB1) is widely expressed in the kidney in both glomeruli and tubules. Our previous studies have elucidated a dichotomous role for EGFR activation in kidney injury, with regulated activation following acute kidney injury (AKI) serving as an important and necessary step for recovery but with persistent and dysregulated activation mediating progressive glomerular and tubulointerstitial injury in progressive kidney diseases. Genetic or pharmacologic inhibition of EGFR activation can be an effective therapeutic intervention in experimental models of chronic kidney disease. Translating this insight into human disease is complicated by known skin side effects of current EGFR tyrosine kinase inhibitors or receptor antibodies. However, given its potential biological relevance, mechanisms to inactivate the EGFR pathway still hold great promise as a therapeutic option, especially if more selective targeting of downstream signaling pathways can be achieved. The mechanisms of EGFR activation in response to acute or chronic kidney injury remain incompletely understood and may involve both ligand- dependent and ligand-independent mechanisms. Furthermore, although recent studies have identified novel mechanisms for augmenting or inhibiting EGFR membrane localization and activation, whether these mechanisms play a role in kidney injury is unknown. The mechanisms and signaling pathways underlying progressive glomerulopathy and tubulointerstitial fibrosis secondary to aberrant EGFR signaling in chronic disease have not be elucidated, nor is is It known whether the same mechanisms mediate EGFR-dependent recovery from AKI. Thus, our overall goal is to determine the molecular mechanisms underlying EGFR-mediated effects in both acute and chronic kidney disease in order to identify more selective therapeutic targets. To accomplish this goal, we propose three specific aims:1) Determine the mechanisms by which EGFR is activated in response to acute or chronic kidney injury. In this aim we will examine both ligand-dependent and ligand- independent mechanisms of EGFR activation in AKI and CKD; 2) determine the mechanisms by which EGFR mediates kidney fibrosis in chronic kidney injury. We will determine the role of EGFR in TGF- production and myofibroblast induction and the role of aberrant YAP/TAZ signaling in EGFR- mediated renal fibrosis; and 3) Determine the mechanisms by which EGFR activation inhibits autophagy. We wil determine the mechanism(s) by which EGFR activation inhibits AMP kinase activity and inhibits autophagy in diabetic nephropathy.

Public Health Relevance

The proposed studies will investigate the role of epidermal growth factor receptor (EGFR) activation in both acute kidney injury and in diabetic nephropathy. The studies will investigate the role of ligand-dependent and ligand-independent EGFR activation in kidney disease, the mechanisms by which chronic EGFR activation mediates glomerulosclerosis and tubulointerstitial fibrosis and mechanisms and consequences of EGFR inhibition of autophagy in diabetic nephropathy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK051265-24
Application #
9614287
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Rys-Sikora, Krystyna E
Project Start
1997-01-01
Project End
2019-12-31
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
24
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Chung, Sungjin; Overstreet, Jessica M; Li, Yan et al. (2018) TGF-? promotes fibrosis after severe acute kidney injury by enhancing renal macrophage infiltration. JCI Insight 3:
Wang, Feng; Katagiri, Daisuke; Li, Ke et al. (2018) Assessment of renal fibrosis in murine diabetic nephropathy using quantitative magnetization transfer MRI. Magn Reson Med 80:2655-2669
Li, Yan; Chung, Sungjin; Li, Zhilian et al. (2018) Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight 3:
Grove, Kerri J; Lareau, Nichole M; Voziyan, Paul A et al. (2018) Imaging mass spectrometry reveals direct albumin fragmentation within the diabetic kidney. Kidney Int 94:292-302
de Caestecker, Mark; Harris, Raymond (2018) Translating Knowledge Into Therapy for Acute Kidney Injury. Semin Nephrol 38:88-97
Zhang, Ming-Zhi; Wang, Suwan; Wang, Yinqiu et al. (2018) Renal Medullary Interstitial COX-2 (Cyclooxygenase-2) Is Essential in Preventing Salt-Sensitive Hypertension and Maintaining Renal Inner Medulla/Papilla Structural Integrity. Hypertension 72:1172-1179
Zhang, Ming-Zhi; Wang, Xin; Wang, Yinqiu et al. (2017) IL-4/IL-13-mediated polarization of renal macrophages/dendritic cells to an M2a phenotype is essential for recovery from acute kidney injury. Kidney Int 91:375-386
Overstreet, Jessica M; Wang, Yinqiu; Wang, Xin et al. (2017) Selective activation of epidermal growth factor receptor in renal proximal tubule induces tubulointerstitial fibrosis. FASEB J 31:4407-4421
Zhang, Ming-Zhi; Wang, Xin; Yang, Haichun et al. (2017) Lysophosphatidic Acid Receptor Antagonism Protects against Diabetic Nephropathy in a Type 2 Diabetic Model. J Am Soc Nephrol 28:3300-3311
Lim, Beom Jin; Yang, Jae Won; Zou, Jun et al. (2017) Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury. Kidney Int 92:1395-1403

Showing the most recent 10 out of 107 publications